Sylvia Chung
Chief Financial Officer
Replay available
Anika Therapeutics (NASDAQ:ANIK) Q4 2019 earnings call, held 2020-02-20. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/anika-therapeutics-inc-anik-q4-2019-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good evening, ladies and gentlemen, and welcome to Anika Therapeutics' fourth quarter and full year 2019 earnings conference call. At this time, all participant lines are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, then 1 on your telephone keypad. Please be advised that today's conference may be recorded. If you require any further assistance, please press star, then 0 to reach an operator. I will now turn the call over to Sylvia Chung, Chief Financial Officer. Please proceed.
0:32 Thank you, Liz. Good evening, everyone, and thank you for joining us. With me on the call today is Dr. Cheryl Blanchard, Interim Chief Executive Officer, and Jim Lurup, Executive Vice President of Business Development and Strategic Planning. During today's call, Cheryl, Jim, and I will review our fourth quarter and full year 2019 financial results and key business highlights, which were summarized in our earnings release issued today. A copy of the earnings release is available on our investor relations section of our website at annacatherapeutics.com. In addition, a slide presentation is posted on our website in the investor relations section under the events and presentations tab.
1:20 We invite you to take a moment now to open a file and follow the presentation along with us. Please turn to slide two. Before we begin, please remember that certain statements made during this conference call constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance, or achievements. Please see our SEC filings for more information about factors that could affect our results. Certain financial measures we will discuss on this call are non-GAAP financial measures.
2:06 We believe that these measures help investors gain a more complete understanding of our results. and is consistent with how management views our financial performance. A reconciliation of these non-GAAP financial results to the most comparable GAAP measurement calculated and presented in accordance with U.S. GAAP is available in the Investor Relations section of our website. I will now turn the call over to our Interim CEO, Dr. Cheryl Blanchard. Cheryl.
2:39 Thank you, Sylvia, and good evening, everyone. Before we discuss our financial results and outlook for the year ahead, I'd like to start by remembering Anika's president and CEO, Joe Darling, who passed away unexpectedly on January 29th. When I interviewed to join Anika's board, Joe talked about Anika and the people who make up Anika with a passion you hope every leader exhibits about his or her company. Joe was a wonderful leader and a trusted colleague who led the beginning of our transformation into a global commercial company. Over the last two and a half years, he set Anika on its current path, reinforcing its strong foundation, leveraging its strengths, and embracing innovation. Most recently, he led the development of our five-year strategic plan, which will continue to guide our growth over the next several years.
3:29 Joe is a great man with a well-deserved reputation in our industry for being a strong leader who is passionate about healthcare. Though certainly we'll miss his leadership, we'll miss his character, humor and friendship even more. Our thoughts and sympathies go out to his wife Maureen and children John and Jordan. We are grateful to Joe for all that he did for Annika and we will continue to work to honor and build on his legacy. Some of you have asked about Joe's passing. While we will continue to respect his family's wish for privacy, I can share that in early 2019, Joe informed the board that he was experiencing some health issues. Following that communication, the Board and Joe were in regular contact regarding his health. He continued to perform his responsibilities well throughout 2019 and into 2020, and over-delivered progress against our strategic goals.
4:25 Based on an ongoing dialogue and Joe's exemplary performance record, the Board remained confident in his ability to lead, and the Board respected Joe's wishes to keep his health condition private. The board designed an interim office of the president in the event Joe might need to take a short leave of absence, which he never needed. His unexpected passing was a shock to all of us here at ANACA, and we are deeply saddened by his loss. Upon learning of Joe's passing, the board activated the interim office of the president to provide immediate ongoing leadership and oversight of ANACA's day-to-day operations while we began the search process to identify ANACA's next CEO. After that time, the Board had an opportunity to consider what would be best for ANACA in light of all the circumstances, and in particular, to consider the impact on the Interim Office of the President structure for the time it would take to conduct the CEO search.
5:23 With the support of the Interim Office of the President, the Board decided to appoint an Interim CEO. I am honored to assume that role and look forward to working alongside the ANACA team to continue delivering for our shareholders and other stakeholders. I have a long history in the biotech and medtech worlds in orthopedics and specifically with joint preservation and regenerative medicine businesses. Given my experience and passion for the field, I was impressed with the company's achievements and excited by its potential. I am confident in the strength of the company's market position and growth prospects. As I step into the role of interim CEO, I am optimistic about the future of the company. During my time on the board, I have gained unique insight into the business, strategy, and operations and have seen firsthand the growth and development of the organization.
6:15 ANACA is well positioned both strategically and financially with a talented team that has deep expertise and an innovative product pipeline. I look forward to working with the board and the management team to capitalize upon the opportunities ahead. Please turn to slide number three. I'd like to now discuss the significant progress that Anika continued to deliver in 2019. Last year, we took significant steps to transform Anika into a global commercial company focused on joint preservation and restoration by executing on our five-year strategic plan. We redeployed resources and added world-class talent to our leadership team, successfully completed the build-out of our small internal hybrid commercial sales force in the U.S., launched our first surgical orthopedic product, Tactuset, under our hybrid commercial model and continue to expand internationally.
7:12 We also recently completed the acquisitions of Parkes Medical and Arthur Surface, which expanded our joint preservation and restoration product portfolio, expanded our commercial capabilities and infrastructure, enhanced our innovative product pipeline, and diversified our revenue base from our successful legacy commercial partners and distributors. These acquisitions accomplished these strategic goals, and more importantly, they strengthened Annika's unique position in the $7 billion sports and regenerative medicine market. They improved our ability to address significant unmet medical needs, which will deliver better patient outcomes and drive sustained revenue growth that will ultimately enhance value for shareholders.
7:57 Please turn to slide number four. Joe often said that our growth strategy is driven by our focus on the three P's, people, products, and performance. And in many ways, our 2019 results and accomplishments are a testament to that continued focus. Let's start with the people. Last year, we added several seasoned executives to our leadership team to enhance our ability to achieve our growth objectives, including Jim Lora, Executive Vice President of Business Development and Strategic Planning, Dr. Bob Richard, Vice President of Research and Development, Steve Goldie, Vice President of U.S. Sales, and Mira Leiwant, Vice President of Regulatory, Quality, and Clinical Affairs. Additionally, we successfully onboarded four highly skilled regional sales directors in the U.S. under our hybrid commercial model.
8:47 These sales directors are currently focused on the full launch of Tacticet. Please turn now to slide five. The recent acquisitions of Parkes Medical and Arthur Surface brought a wealth of talent into our organization and further enhanced our commercial capabilities and infrastructure. Combined, they added approximately 40 sales reps and more than 150 distributors in the U.S. to our hybrid commercial model and over 70 international distributors. These acquisitions enabled us to achieve a level of commercial scale far more efficiently and quickly than greenfielding a commercial team. We are excited to fully deploy our hybrid commercial model, which will provide ANACA with a direct line of sight to the market and deliver more favorable economic results.
9:37 Turning to slide six, in December, we commenced the full-scale commercial launch of Tacticet in the US at the 2019 Orthopedic Summit and Evolving Techniques Conference, or OSET. Nearly 100 procedures have been completed to date and we continue to receive positive feedback from the physician community regarding the therapy's ease of use and procedural efficiency. In 2019, we surpassed our initial goals of onboarding five distributors with product availability in 10 surgical centers. To date, we have onboarded 17 new distributors and we plan to grow and leverage the distribution networks at Arthur Surface and Parkis. For 2020, We expect revenue from Tacticet to be approximately $3 million.
10:24 Product development for our rotator cuff repair therapy is progressing according to plan. We continue to anticipate that we will submit a 510K application to the FDA in the early 2021 timeframe. This therapy is highly synergistic with many product offerings at Parkes Medical and Arthur Surface. Please turn to slide number seven. Singhal, our novel third-generation visco-supplementation therapy combining HA and steroid, continued to deliver strong performance in Canada and across Europe. International revenue from Singhal grew close to 30% year-over-year in 2019. The continued growth of Singhal, coupled with the strong feedback from both doctors and patients, has reinforced our confidence as we advance Singhal towards regulatory approval in the U.S. market.
11:17 We remain on track to initiate the Singdahl pilot study in the first half of 2020. We are in the process of preparing for U.S. site initiation and patient enrollment. We expect this study to confirm our trial design, increase our probability of success in a Phase III trial, and generate data that ultimately will be needed to support FDA approval. There are three key differentiators in this revised protocol compared to the prior Phase III 1602 study. The first is the inclusion of a placebo arm. The second is the addition of a much larger steroid arm. And the third is the modification of the patient enrollment selection criteria for targeting our ideal patient profile. We continue to expect that the pilot study will take approximately one year to complete.
12:05 We remain confident in Syngal's U.S. market opportunity, which we estimate to be approximately $1 billion annually. Please turn to slide eight. On the regenerative medicine front, we've advanced the clinical development for our cartilage repair therapy, Hylafast. During the fourth quarter, we continued work on adding new sites, especially internationally, and we expect to initiate 10 new sites in the first half of 2020. The trial is currently close to 70% enrolled, and we continue to expect to complete patient enrollment by the end of 2020. I am excited about Annika's momentum confident in our market position and the opportunities ahead, and look forward to the continued execution of our plan.
12:53 With that, I will now turn the call over to Jim Laurup to discuss our integration plans for the Parkes Medical and Arthur Surface businesses. Jim?
13:03 Thank you, Cheryl. Please turn to slide nine. I will start by discussing our integration plans for Parkes Medical and Arthur Surface and touch on some of the key targets that we are looking to achieve in the near term. Similar to how our acquisitions were focused on delivering growth, we view the integration process as a growth story. We are deploying an efficient matrix organization with local management. Our focus is on adding capabilities rather than consolidating them. When we first announced the acquisitions, we were confident that both Parkes Medical and Arthur Surface were highly synergistic with Anika's technology platform, and that has become even more evident following the completion of both transactions. Thank you for joining us.
14:10 Our goal is to focus on product portfolio cross-training and leverage our consolidated distribution network to commercialize tap-to-set. Longer term, our goal is to optimize our commercial infrastructure, reap the benefits from cross-selling, and increase profitability. The acquisitions of Parkes Medical and Arthur Surface also expand our innovative product pipeline and enable us to increase the number of new products we will bring to market in the coming years. We are currently using our StageGate process to evaluate our enhanced pipeline following these acquisitions and prioritize resources towards supporting programs with the highest growth potential. We will share a pipeline roadmap later this year after completing this assessment.
14:57 In the near term, we expect that the acquisitions will be accretive to earnings on a non-GAAP basis by the end of 2021, deliver double-digit revenue growth, and contribute to achieving a vitality index at above 25%. I will now turn the call over to Sylvia to review our fourth quarter and full year 2019 financial results. Sylvia.
15:22 Thank you, Jim. Please turn to slide 10. Total revenue for the fourth quarter increased 10% year over year to $29.8 million. compared to $27 million for the fourth quarter of 2018. Revenue growth for the quarter was driven primarily by global VSCO supplement products, which delivered worldwide growth of 11% year over year. Total revenue for the full year of 2019 increased 9% to $114.6 million compared to $105.6 million for 2018. Domestic fiscal supplement revenue increased 8% year-over-year for the quarter.
16:09 During the fourth quarter, U.S. end-user average selling price increased around mid-single-digit for both Orfavisk and Monovisk on a year-over-year basis. On a sequential quarter basis, U.S. end-user net average selling price decreased in the single-digit percent range for Orfavisk and Monovisk. On a year-over-year basis, and user volume for the quarter increased 5% for Orfavisc and 13% for Monovisc. International VSCO supplement revenue increased 24% and 20% year over year for the quarter and for the full year respectively. Product growth margin was 71% for the quarter compared to 74% for the fourth quarter of 2018.
17:00 The year-over-year decrease was primarily due to certain inventory charges and changes in the product revenue mix. For the full year of 2019, we delivered a strong product gross margin of 75%. Total operating expenses in the quarter were $25 million compared to $17.2 million in the fourth quarter of 2018. The year-over-year increase in total operating expenses was due primarily to higher SG&A expenses related to the acquisitions of Parkes Medical and OrthoSurface, the US commercial launch of TactileSet, as well as the higher cost of product revenue.
17:45 Acquisition costs totaled 2.9 million for the fourth quarter of 2019. For the full year, total operating expenses were 80.4 million compared to 83.8 million for 2018. Net income for the quarter was $4.1 million, or $0.28 per diluted share, compared to $7.7 million, or $0.54 per diluted share in the fourth quarter of 2018. Excluding acquisition costs, adjusted non-GAAP net income for the fourth quarter of 2019 was $6.3 million, or $0.43 per diluted share. For the full year, Net income increased by $8.5 million to $27.2 million, or $1.89 per diluted share, compared to $18.7 million, or $1.27 per diluted share for 2018.
18:36 Excluding the acquisition costs, adjusted net income for the full year of 2019 was $29.4 million, or $2.05 per diluted share. Adjusted EBITDA was $11.1 million for the quarter compared to $12.2 million for the fourth quarter of last year. For the full year, Adjusted EBITDA increased 27% to $49.2 million compared to $38.7 million for 2018. Adjusted EBITDA is defined by the company as U.S.
19:23 GAAP net income excluding depreciation and amortization, interest and other income or expense, income taxes, share-based compensation expense, and acquisition-related expenses. In 2019, acquisition-related expenses consisted of investment banking, legal, accounting, and other professional and related fees associated with the orthosurface and Parkes Medical transactions. These are costs that the company would not have incurred except as a direct result of the acquisitions. For the 12 months ended December 31st, 2019, we generated approximately $37 million in cash from operating activities and approximately $22 million in cash from employee stock option exercises.
20:17 We ended the year with cash and investments totaling $185 million. In the first quarter of 2020, We used 95 million from existing cash on our balance sheet to fund the acquisitions of Parkes Medical and OrthoSurface. We also completed our 30 million accelerated share repurchase program in January of 2020. Since May 2019, we have repurchased approximately 600,000 shares of common stock under that program. We have not yet had any shares repurchased under the Board-approved $20 million Open Market Repurchase Program. We will continue to take a disciplined approach to capital allocation to ensure we're deploying our capital to the opportunities with the greatest potential to create shareholder value.
21:12 Please turn to slide 11 to review our guidance and key initiatives for 2020. Total operating expenses For the full year of 2020, we expect total revenue to be in the $160 to $165 million range, and total operating expenses for the year are expected to be in the $150 to $155 million range. This includes purchase accounting, acquisition and integration costs, which is currently estimated to be around $27 million for the year, most of which are non-cash charges.
21:58 Product gross margin for 2020 is expected to be around the low 60% range due to acquisition accounting and related one-time inventory fair value markups. We expect product gross margin to return to the 70% range in 2021. Research and development expenses as a percentage of revenue is expected to increase in 2020 due primarily to the initiation of the Sengal Pilot Study and advancement of ongoing development programs. Selling general and administrative expenses as a percentage of revenue is also expected to be higher in 2020 as a result of our enhanced commercial capabilities and infrastructure from the acquisitions of Parkes Medical and Arthrosurface.
22:49 As Jim discussed earlier, we plan to optimize our global distribution network following the integration to drive SG&A efficiencies. For the full year of 2020, adjusted EBITDA is expected to be in the high $40 to high $50 million range based on a GAAP net income expectation in the $5 to $12 million range. Non-GAAP adjusted net income is expected to be in the mid-20 to low $30 million range. Adjusted EBITDA and net income exclude expenses related to acquisition accounting and non-recurring integration charges currently estimated to be around $27 million for the year, most of which, again, are non-cash charges.
23:39 Capital expenditure for the year are expected to be between $5 and $7 million, primarily for manufacturing and operations automation initiatives. I would like to emphasize that this guidance reflects our best estimates for the very recently acquired Arcosurface and Parkas businesses. These transactions closed in late January and early February of this year. The final fair value determination of acquisition-related purchase accounting may differ from the preliminary estimates once ANACA's valuation of the fair value of tangible and intangible assets acquired and liabilities assumed have been completed. And those differences could be material.
24:25 In 2020, our disciplined financial plan is focused on the following four key initiatives. successfully integrating Parkis Medical and Arthrosurface, including a refreshed product pipeline roadmap in the third quarter of 2020. Second, continuing to execute the U.S. commercial launch of TactoSET and expanding our VSCO supplement and surgical product portfolios globally. Third, commencing the Sengal pilot study in the first half of 2020 to advance the therapy toward regulatory approval in the U.S. Fourth, advancing our regenerative medicine product pipeline, including Halifast, rotator cuff repair therapy, and other development programs.
25:14 Lastly, with the acquisitions of Parkes Medical and Arthrosurface, we significantly expanded our product portfolio beyond our historical focus on osteoarthritis pain management into therapies for joint preservation and restoration. Going forward, we will report revenue for three product lines. First is the Joint Pain Management Therapy, which includes the human and animal visco-supplement products. Second is the Orthopedic Joint Preservation and Restoration Care products, which include TactilSET, HydroFast, and sports medicine surgical products from Parkes Medical and Arthrosurface. And lastly, the Other category, which includes legacy products such as ophthalmology, advanced wind care, anti-ahesion surgical products, and aesthetic dermatology products.
26:09 Thank you very much for your attention. I would now turn the call back over to Cheryl.
26:15 Thank you, Sylvia. We're pleased with the company's performance in 2019 and look forward to continuing our momentum in 2020. We are well positioned to achieve our strategic initiatives and we are confident that we are becoming a leader in sports and regenerative medicine while also doubling our total revenue over the next five years. We're now happy to take your questions. Thank you. As a reminder, ladies and gentlemen, to ask a question, you will need to press star then one on your telephone keypad. To withdraw your question, press the pound key. In the interest of time, we ask that you limit yourself to one question and one follow-up question, then rejoin the queue for any additional questions. Our first question comes from the line of Joe Munda with First Analysis.
27:00 Your line is now open.
27:03 Good afternoon. Can you hear me okay?
27:05 Yes, we can. Joe, hi. Good afternoon.
27:07 Good afternoon. First off, I want to convey our sincerest condolences regarding the passing of Joe. He was a really, really great guy to work with. That being said, I wanted to talk to you a little bit about the guidance in the quarter. In regards to the quarter itself, can you give us some sense of what the split was in the mix, Monavis, OrthoVisc, and then maybe the contribution from Singhal in the quarter? And then my second question in regards to the guidance, can you give us some sense of what the incremental contribution will be from Parkis and Arthurservice in 2020 in terms of your forecast? Thank you.
27:48 Okay. So I think I just want to make sure. The first question is on Orfavis-Monavis mix, and the second is on Singhal, and then the third question is on the revenue contribution from Parkis and Orfavis. In terms of the split of revenue for Monavis and Orfavis, Monavis is roughly 45% to 50% of our total revenue for the year. and OrphoVisc is roughly between 35 to 40% of our total revenue for the year. Singhal continued to grow very strongly and we had mentioned that for the year, the growth year over year is close to 30% and as a percent of total revenue is roughly about 5% of our total revenue.
28:43 For the year?
28:45 For the year. for the year. Yeah, we would like to stick to commenting on year just because of the inherent quarterly variability because of our distributor model. Yep, so thank you for your understanding on that. With regards to revenue contributions, so we provided our consolidated total revenue guidance for the year, which is between $160 to $165 million. We do not plan to provide guidance on a company-by-company basis. Having that said, I can reiterate, Parkis, from a historical standpoint, they achieved $13 million of revenue in 2019 and delivered 15% growth year-over-year for 2019.
29:34 And OrthoSurface revenue for 2019 was $30 million, and they achieved 10% growth year-over-year from 2018 to 2019. and our expectation is that they will continue double-digit growth this year and into the future.
29:51 Okay. Thank you.
29:53 You're welcome. Our next question comes from the line of Mike Pitesky with Barrington Research. Your line is now open.
30:01 Good evening. I guess just from a modeling perspective, are you going to sort of separately, you know, in terms of these new businesses, are you going to break them out? Are they going in other revenue? How are you disclosing that piece of the business going forward?
30:19 Yep. So from a reporting standpoint, we'll consolidate Parkes and Arkel Surface. The revenue product families will be recasted. Instead of having the historical orthobiologics, surgical, dermal, and other, we will be recasting the revenue into three revenue product lines or three families. So joint pain management would be a human and animal visco-supplement products, meaning Orfavisq, Monavisq, Syngal, and Hivisq. Preservation and restoration care products will be the surgical products from Parkis and Arthrosurface, as well as our own legacy surgical products like Halofast, as well as Tactifet, which is newly launched in December of 2019.
31:14 All the other product lines, the ophthalmic products, the wound care, dermatology products, and anti-ahesion products, will be grouped in the other category. I think this provides a better visibility in terms of understanding our office-based products, which would now be in the pain management category, and the operating room-based surgical products, which we have full control of because of our hybrid and direct sales model. And that would be in the orthopedic joint preservation and restoration care product line. So hopefully that's clear and it's helpful for you, Mike.
31:51 You probably added an hour to my evening just telling me that. Thank you. Yeah, we'll figure it out. And then in terms of the integration expenses, is that just going into SG&A or is it going to be a separate line item for that each quarter going forward?
32:13 Yep. on the estimate, the preliminary estimated purchase accounting integration and acquisition costs, it's roughly about $27 million. There are really three buckets and Most, the majority of that will go through the cost of goods sold line, which is related to purchase price accounting and having to mark up the inventory balance to fair value. And this was the reason why In the script section, I mentioned that the product gross margin expectation for 2020 is in the low 60% range, and that is due to the result of purchase price accounting having to mark up inventory.
33:06 And the remaining portion will primarily go through SG&A. Okay, okay.
33:12 And then just in this quarter, do you by any chance have CapEx for the fourth quarter handy?
33:22 CapEx is roughly about $300,000 for the fourth quarter and close to $3 million for the year.
33:31 And just, I guess, one other question. Is there any change in emphasis, strategic vision, in terms of the leadership transition, capital allocation priorities. Is there any change relative to what we had been hearing the past six to 12 months? Thank you.
33:58 Hi, Mike. This is Cheryl. I'll take that one. I would let you know that there are no changes, that the five-year strategic plan that we've been talking about is The way we're moving forward and nothing has changed in that regard, so no change in assumptions there.
34:16 Okay. All right. Great. Thank you very much. You're welcome. Our next question comes from the line of Jim Sidoti with Sidoti & Company. Your line is now open.
34:27 Hi. Good afternoon. Can you hear me?
34:30 Yes, we can, Jim.
34:32 Great. I just want to get some more color on that. will all be charged $27 million of integration charges in 2020. Will that all be one time, and will those occur at all in 2021? Yep.
34:50 So most of that charge would be One Time, and most of it is non-cash. And I think it may be helpful, given the size and the fact that there's a repeat question, for me to provide a little bit more color. Earlier, I was saying that there are three buckets of these acquisition-related expenses. The first bucket is really purchase price accounting. which includes fair valuation of assets and related amortization costs. So the majority of the valuation is gonna be based on what we have at this point will be on inventory. And that charge is non-cash and we expect that majority of that will flow through 2020.
35:40 So that's a one-time event. Some of the purchase price accounting will have and many more. And I'll get into at a high level the split. Acquisition costs is going to be related to banking, legal accounting and other professional costs and those are purely one time. And integration related expenses are routine in nature from the integration standpoint. These are professional fees and some of it is related to, will be related to system costs and those will be one time as well. So when we look at the $27 million estimate, I would say that roughly about 80% of that would be non-cash and the majority of that will be one time charges.
36:38 Okay, and will there be more in the first quarter because that's when the deal is closed, or will it be spread out throughout the year?
36:47 Yep. So from a timing standpoint, I would say roughly about a third would be in the first quarter, and this is due to the timing of the closings of Parcus and Arthosurface transactions. And the remainder will be roughly evenly spread between Q2 and Q4 of this year.
37:10 Okay, so based on your share count, you're talking about a hit of about $1.30 a share, and you're saying about 40 cents of that will wind up in the first quarter?
37:24 Roughly, yes.
37:26 Okay, thank you. We have a follow-up question from the line of Joe Mundo with First Analysis. Your line is now open.
37:40 Sorry, Sylvia, I was on mute. Real quick, so if we were to back out that impact to gross margin essentially from the 27 million, I know you have some data and I'm trying to run through the numbers here, but what would product gross margin be without the impact of the 27? Would it still be in the mid to low 70s for 2020?
38:10 We're not in a position to break out the business and the different line items on the P&L with and without the acquisition. What I can share is that the reason why the product gross margin is expected to be in the low 60% range, comparing to the previous historical 70% product growth margin achievement is due to the non-cash acquisition related, the expected estimated non-cash acquisition related adjustment. We do expect that starting 2021 we'll be back to the historical level of product growth margin.
39:00 Okay, so there's nothing else in there other than the acquisition related Charges that is driving gross margin down. Is that the way to think about it?
39:14 Yeah, I think there are a number of factors, as you know. The largest one is the non-cash item that I spoke about. On the prior investor call, we had talked about the product gross margin for the two acquired businesses are slightly lower than ANACA's historical consolidated product gross margin. So that is one factor, but it's a smaller factor. and product gross margin, as you know, is also directly impacted by pricing. So I don't think on this call it's appropriate to get into a detailed discussion on each of these points. The key takeaway is the main driver for the product gross margin to be in the low 60% range is due to one-time non-cash charges related to The Parkis and Orthosurface acquisitions.
40:14 Okay. And then just one more here. And then on the adjusted EBITDA that you're looking for, 47 to 57 million, in your prior comments regarding the acquisition, you know, you were talking about them weighing on EBITDA or having a The impact in 20 and then bouncing back in 21 and being non-GAAP profitable as a result. Can you give us some sense of what the impact to EBITDA is from the combined businesses in 20 and the expectation?
40:48 Yep. Our policy is to provide the EBITDA guidance and expectation on a consolidated business standpoint and not break into the individual business entities. What I can share with you is our goal and we have plans in place and are on our pathway to achieve those is to have the two acquired businesses be EBITDA positive as well as be net income Non-GAAP net income positive or accretive for us starting in 2021. Okay. Okay.
41:31 Thanks. We have a follow-up question from the line of Mike Petoskey with Barrington Research. Your line is now open.
41:42 Yeah, so Sylvia, on the effective tax rate, it looks like you guys are expecting more like mid-30s in 20, and could you just, I guess, explain that and then talk about is that sort of the new normal as we move forward, or do we go back post the integration of all this to sort of a mid-20s range for effective tax rate? Thanks.
42:06 Yep. The current expectation on the effective tax rate is in the mid to high 20% range. Obviously, as you can imagine, after the acquisition of two new entities, there's a fair amount of work to do on a number of fronts, including purchase price accounting, looking at the tax positions for each of the three individuals. So there's a lot of work a lot of detailed work that we're currently focusing on and we'll look to update and provide additional information in future quarters. The information that we have provided in the earnings release as well as on this Investor Call are based on our best estimates.
43:00 And as you all know, the acquisitions just recently closed within the last few weeks. We've done a lot of work in terms of looking at the two businesses and put together our best set of estimates. And throughout this year, we'll be looking to report actuals and providing information on the differences and any material updates that we have.
43:25 Okay, so I'm looking at page three of the release where you essentially say estimated provision for income tax is $1.7 million on net income of $5 million. Obviously, that's 34%, and it's the same for the high-end of the range. Are you saying that your estimate is now lower than what's in this release, or am I just misunderstanding, which is very possible at this point?
43:48 Yeah, I think there's On page three of the earnings release, if you're looking at the estimated provision for income tax, that should equate to about mid-20 to high 20%.
44:04 Okay, I see. Sorry, it's against pre-tax. Sorry, I've been here 14 hours already today. Sorry. Sorry, Sylvia. Thank you. Thank you very much. Thanks. You're welcome. I'm showing no further questions in queue at this time. I'd like to turn the call back to Cheryl Blanchard for closing remarks.
44:23 Thank you for your time today. We look forward to updating you as we continue to deliver progress toward our strategic initiatives. Thank you and have a great evening.
Follow Anika Therapeutics Inc. into a list and get an email when it puts out news.
Chief Financial Officer
Interim Chief Executive Officer
Executive Vice President, Business Development and Strategic Planning
Analyst, First Analysis
Analyst, Barrington Research
Analyst, Sidoti & Company